Smoking During Pregnancy Affects Newborn Behavior According to New Study.

Business Editors/Health/Medical Writers

MAYWOOD, N.J.--(BUSINESS WIRE)--June 4, 2003

Nymox (Nasdaq:NYMX) NicAlert Product Can Help Detect and Monitor

Level of Smoking During Pregnancy

A new published study has found that smoking during pregnancy is associated with newborns who are more excitable, less consolable and more rigid.

Overall those newborns show signs of stress similar to those found in babies of mothers addicted to cocaine or heroin. The study by researchers from Brown Medical School published in Pediatrics (2003; 111:1318-1323), the official journal of the American Academy of Pediatrics, also found that the more the nicotine exposure as measured by cotinine levels in the pregnant mothers, the more there were signs of stress seen in the newborns.

A recent comprehensive review of earlier studies relating lifestyle factors in pregnancy, including smoking, to attention deficit hyperactivity disorder (ADHD) found evidence of a link between smoking during pregnancy and ADHD later in childhood: American Journal of Psychiatry (2003: 160: 1028-40).

"For years we have known that smoking during pregnancy leads to lower birthweights. This new study shows that smoking even relatively few cigarettes a day can have an adverse effect on the behavioral functioning of newborn infants," said Dr. Michael Munzar, Medical Director of Nymox. "Our NicAlert(TM) product provides an easy cost-effective way of measuring cotinine levels in urine. This product permits physicians and nurses to determine whether a pregnant mother-to-be is smoking and to initiate counseling. Sometimes pregnant women are reluctant to admit to smoking. NicAlert(TM) allows for the routine screening of patients for smoking and so enables appropriate intervention early on in the pregnancy."

NicAlert(TM) is a powerful one-step semi-quantitative urine test for detecting smoking and tobacco product exposure that received clearance for medical use from the U.S. FDA in October 2002. NicAlert(TM) provides the capability of measuring cotinine levels in an easy-to-use, cost effective, rapid format. The NicAlert(TM) product does not require any instruments or special training for its use.

Nymox Pharmaceutical Corporation also announced today that the results of a large European clinical trial showed that Nymox's NicAlert(TM) product can help smokers quit. The study found significant smoking reduction over the four-month trial period when NRT was combined with individual cotinine levels as measured by NicAlert(TM). The study of NRT with NicAlert(TM) was undertaken at the Hirslanden Lung Center Zurich, Switzerland. The lead investigator was Dr. Karl Klingler. Some results from this study were presented at the 75th anniversary of the Congress of Swiss Pneumologists in St. Gallen, Switzerland. The authors of the study were Karl Klingler, Jurg Barandun, Thomas Scherer, Beat Walder, Harald Rinde and Jorge Wernli. Further results will be presented at the 12th World Conference on Tobacco or Health in Helsinki August 3-8, 2003.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.